Cargando…

Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment

Antivirals already on the market and expertise gained from the SARS and MERS outbreaks are gaining momentum as the most effective way to combat the coronavirus outbreak. SARS-CoV-2 has caused considerable mortality due to respiratory failure, highlighting the immediate need for successful therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Chavda, Vivek P., Gajjar, Normi, Shah, Nirav, Dave, Divyang J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Masson SAS. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532500/
https://www.ncbi.nlm.nih.gov/pubmed/36575695
http://dx.doi.org/10.1016/j.ejmcr.2021.100013
_version_ 1784587084215877632
author Chavda, Vivek P.
Gajjar, Normi
Shah, Nirav
Dave, Divyang J.
author_facet Chavda, Vivek P.
Gajjar, Normi
Shah, Nirav
Dave, Divyang J.
author_sort Chavda, Vivek P.
collection PubMed
description Antivirals already on the market and expertise gained from the SARS and MERS outbreaks are gaining momentum as the most effective way to combat the coronavirus outbreak. SARS-CoV-2 has caused considerable mortality due to respiratory failure, highlighting the immediate need for successful therapies as well as the long-term need for antivirals to combat potential emergent mutants of coronaviruses. There are constant viral mutations are being observed due to which world is experiencing different waves of SARS-CoV-2. If our understanding of the virology and clinical presentation of COVID-19 grows, so does the pool of possible pharmacological targets. In COVID-19, the difficulties of proper analysis of current pre-clinical/clinical data as well as the creation of new evidence concerning drug repurposing will be crucial. The current manuscript aims to evaluate the repurposing of an anti-HIV drug Darunavir Ethanolate in COVID-19 treatment with in silico study and we discuss the therapeutic progress of Darunavir Etanolate, to prevent SARS-CoV-2 replication, which supports its clinical assessment for COVID-19 therapy.
format Online
Article
Text
id pubmed-8532500
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-85325002021-10-22 Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment Chavda, Vivek P. Gajjar, Normi Shah, Nirav Dave, Divyang J. Eur J Med Chem Rep Article Antivirals already on the market and expertise gained from the SARS and MERS outbreaks are gaining momentum as the most effective way to combat the coronavirus outbreak. SARS-CoV-2 has caused considerable mortality due to respiratory failure, highlighting the immediate need for successful therapies as well as the long-term need for antivirals to combat potential emergent mutants of coronaviruses. There are constant viral mutations are being observed due to which world is experiencing different waves of SARS-CoV-2. If our understanding of the virology and clinical presentation of COVID-19 grows, so does the pool of possible pharmacological targets. In COVID-19, the difficulties of proper analysis of current pre-clinical/clinical data as well as the creation of new evidence concerning drug repurposing will be crucial. The current manuscript aims to evaluate the repurposing of an anti-HIV drug Darunavir Ethanolate in COVID-19 treatment with in silico study and we discuss the therapeutic progress of Darunavir Etanolate, to prevent SARS-CoV-2 replication, which supports its clinical assessment for COVID-19 therapy. The Author(s). Published by Elsevier Masson SAS. 2021-12 2021-10-22 /pmc/articles/PMC8532500/ /pubmed/36575695 http://dx.doi.org/10.1016/j.ejmcr.2021.100013 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Chavda, Vivek P.
Gajjar, Normi
Shah, Nirav
Dave, Divyang J.
Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment
title Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment
title_full Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment
title_fullStr Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment
title_full_unstemmed Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment
title_short Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment
title_sort darunavir ethanolate: repurposing an anti-hiv drug in covid-19 treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532500/
https://www.ncbi.nlm.nih.gov/pubmed/36575695
http://dx.doi.org/10.1016/j.ejmcr.2021.100013
work_keys_str_mv AT chavdavivekp darunavirethanolaterepurposinganantihivdrugincovid19treatment
AT gajjarnormi darunavirethanolaterepurposinganantihivdrugincovid19treatment
AT shahnirav darunavirethanolaterepurposinganantihivdrugincovid19treatment
AT davedivyangj darunavirethanolaterepurposinganantihivdrugincovid19treatment